Advanced search
Publication Cover
International Journal of Nanomedicine Volume 7, 2012 - Issue
Submit an article Journal homepage
69
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Effect of magnetic nanoparticles of Fe3O4 and wogonin on the reversal of multidrug resistance in K562/A02 cell line

Jian Cheng1 Department of Hematology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing, People’s Republic of China
,
Lin Cheng1 Department of Hematology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing, People’s Republic of China
,
Baoan Chen1 Department of Hematology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing, People’s Republic of China;2 Department of Oncology of Southeast University, Nanjing, People’s Republic of ChinaCorrespondence[email protected]
,
Guohua Xia1 Department of Hematology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing, People’s Republic of China
,
Chong Gao1 Department of Hematology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing, People’s Republic of China
,
Huihui Song1 Department of Hematology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing, People’s Republic of China
,
Wen Bao1 Department of Hematology, Key Medical Disciplines of Jiangsu Province, Zhongda Hospital, Medical School of Southeast University, Nanjing, People’s Republic of China
,
Qinglong Guo3 Key Laboratory of Carcinogenesis and Intervention of Jiangsu Province, China Pharmaceutical University, Nanjing, People’s Republic of China
,
Haiwei Zhang3 Key Laboratory of Carcinogenesis and Intervention of Jiangsu Province, China Pharmaceutical University, Nanjing, People’s Republic of China
&
Xuemei Wang4 State Key Laboratory of Bioelectronics, Southeast University, Nanjing, People’s Republic of China
 show all
Pages 2843-2852 | Published online: 08 Jun 2012

Figures & data

Figure 1 Distribution of nanoparticles in K562/A02 cells incubated with and without 10% (v/v) magnetic nanoparticles for 48 hours.

Notes: (A) Transmission electron micrograph for control, (B) transmission electron micrograph for 10% (v/v) magnetic nanoparticles, red arrows direct nanoparticles in the endosome vesicles, and the upper left and upper right pictures were the magnifications (10×), (C) Prussian blue staining for control, and (D) Prussian blue staining for 10% (v/v) magnetic nanoparticles.

Figure 1 Distribution of nanoparticles in K562/A02 cells incubated with and without 10% (v/v) magnetic nanoparticles for 48 hours.Notes: (A) Transmission electron micrograph for control, (B) transmission electron micrograph for 10% (v/v) magnetic nanoparticles, red arrows direct nanoparticles in the endosome vesicles, and the upper left and upper right pictures were the magnifications (10×), (C) Prussian blue staining for control, and (D) Prussian blue staining for 10% (v/v) magnetic nanoparticles.

Figure 2 (A) Viability of K562/A02 cells treated with different concentrations of magnetic nanoparticles, (B) viability of K562/A02 cells treated with different concentrations of wogonin, (C) surviving fraction of K562/A02 cells treated with 20 μmol/L wogonin or 0.1 (v/v) magnetic nanoparticles for 24, 48, and 72 hours, (D) inhibition rates of K562/A02 cells treated with different concentrations of daunorubicin with and without magnetic nanoparticles for 48 hours, (E) inhibition rates of K562/A02 cells treated with coadministered daunorubicin + wogonin with and without magnetic nanoparticles for 48 hours, (F) IC50 of daunorubicin treated with daunorubicin, daunorubicin + wogonin, daunorubicin magnetic nanoparticles, and daunorubicin-wogonin magnetic nanoparticles for 24, 48, and 72 hours.

Abbreviations: DNR, daunorubicin; Wog, wogonin; MNPs, magnetic nanoparticles; IC50, inhibitory concentration at 50%.

Figure 2 (A) Viability of K562/A02 cells treated with different concentrations of magnetic nanoparticles, (B) viability of K562/A02 cells treated with different concentrations of wogonin, (C) surviving fraction of K562/A02 cells treated with 20 μmol/L wogonin or 0.1 (v/v) magnetic nanoparticles for 24, 48, and 72 hours, (D) inhibition rates of K562/A02 cells treated with different concentrations of daunorubicin with and without magnetic nanoparticles for 48 hours, (E) inhibition rates of K562/A02 cells treated with coadministered daunorubicin + wogonin with and without magnetic nanoparticles for 48 hours, (F) IC50 of daunorubicin treated with daunorubicin, daunorubicin + wogonin, daunorubicin magnetic nanoparticles, and daunorubicin-wogonin magnetic nanoparticles for 24, 48, and 72 hours.Abbreviations: DNR, daunorubicin; Wog, wogonin; MNPs, magnetic nanoparticles; IC50, inhibitory concentration at 50%.

Figure 3 Apoptotic rates of K562/A02 cells incubated for 48 hours by flow cytometry. (A) control, (B) 2 μmol/L daunorubicin, (C) 0.1 (v/v) magnetic nanoparticles, (D) 20 μmol/L wogonin, (E) combination of 2 μmol/L daunorubicin and 20 μmol/L wogonin, (F) 2μmol/L daunorubicin magnetic nanoparticles (at a molar ratio of 2:100), (G) 2 μmol/L daunorubicin-wogonin magnetic nanoparticles (at a molar ratio of 2:20:100).

Figure 3 Apoptotic rates of K562/A02 cells incubated for 48 hours by flow cytometry. (A) control, (B) 2 μmol/L daunorubicin, (C) 0.1 (v/v) magnetic nanoparticles, (D) 20 μmol/L wogonin, (E) combination of 2 μmol/L daunorubicin and 20 μmol/L wogonin, (F) 2μmol/L daunorubicin magnetic nanoparticles (at a molar ratio of 2:100), (G) 2 μmol/L daunorubicin-wogonin magnetic nanoparticles (at a molar ratio of 2:20:100).

Figure 4 Intracellular accumulation of daunorubicin in K562/A02 cells cultured with different drugs for 48 hours. (A) Control, (B) 2 μmol/L daunorubicin, (C) combination of 2 μmol/L daunorubicin combined with 20 μmol/L Wog, (D) 2 μmol/L daunorubicin magnetic nanoparticles (at a molar ratio of 2:100), (E) 2 μmol/L daunorubicin-Wog magnetic nanoparticles (at a molar ratio of 2:20:100), (F) relative fluorescence intensity of daunorubicin in treated cells.

Abbreviations: DNR, daunorubicin; Wog, wogonin; MNPs, magnetic nanoparticles; RFI, relative fluorescence intensity.

Figure 4 Intracellular accumulation of daunorubicin in K562/A02 cells cultured with different drugs for 48 hours. (A) Control, (B) 2 μmol/L daunorubicin, (C) combination of 2 μmol/L daunorubicin combined with 20 μmol/L Wog, (D) 2 μmol/L daunorubicin magnetic nanoparticles (at a molar ratio of 2:100), (E) 2 μmol/L daunorubicin-Wog magnetic nanoparticles (at a molar ratio of 2:20:100), (F) relative fluorescence intensity of daunorubicin in treated cells.Abbreviations: DNR, daunorubicin; Wog, wogonin; MNPs, magnetic nanoparticles; RFI, relative fluorescence intensity.

Figure 5 Transcription of MDR1 mRNA after treatment for 48 hours.

Abbreviations: DNR, daunorubicin; MNPs, magnetic nanoparticles; Wog, wogonin.

Figure 5 Transcription of MDR1 mRNA after treatment for 48 hours.Abbreviations: DNR, daunorubicin; MNPs, magnetic nanoparticles; Wog, wogonin.

Figure 6 Expression of P-glycoprotein after treatment for 48 hours.

Abbreviations: DNR, daunorubicin; MNPs, magnetic nanoparticles; Wog, wogonin.

Figure 6 Expression of P-glycoprotein after treatment for 48 hours.Abbreviations: DNR, daunorubicin; MNPs, magnetic nanoparticles; Wog, wogonin.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.